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Abstract
Large-scale molecular profiling technologies have assisted the identification of disease biomarkers and facilitated the basic
understanding of cellular processes. However, samples collected from human subjects in clinical trials possess a level of
complexity, arising from multiple cell types, that can obfuscate the analysis of data derived from them. Failure to identify,
quantify, and incorporate sources of heterogeneity into an analysis can have widespread and detrimental effects on
subsequent statistical studies. We describe an approach that builds upon a linear latent variable model, in which expression
levels from mixed cell populations are modeled as the weighted average of expression from different cell types. We solve
these equations using quadratic programming, which efficiently identifies the globally optimal solution while preserving
non-negativity of the fraction of the cells. We applied our method to various existing platforms to estimate proportions of
different pure cell or tissue types and gene expression profilings of distinct phenotypes, with a focus on complex samples
collected in clinical trials. We tested our methods on several well controlled benchmark data sets with known mixing
fractions of pure cell or tissue types and mRNA expression profiling data from samples collected in a clinical trial. Accurate
agreement between predicted and actual mixing fractions was observed. In addition, our method was able to predict
mixing fractions for more than ten species of circulating cells and to provide accurate estimates for relatively rare cell types
(,10% total population). Furthermore, accurate changes in leukocyte trafficking associated with Fingolomid (FTY720)
treatment were identified that were consistent with previous results generated by both cell counts and flow cytometry.
These data suggest that our method can solve one of the open questions regarding the analysis of complex transcriptional
data: namely, how to identify the optimal mixing fractions in a given experiment.
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Introduction
With its capacity for simultaneous monitoring of the transcrip-
tional state of thousands of genes, high-throughput transcriptional
profiling using DNA microarrays has provided investigators with a
unique opportunity for genome-wide regulatory analysis in clinic
trials and biomarker identification. Molecular analysis of cells in
their native tissue environment provides the most accurate picture
of the in vivo disease state [1]. The complicated structures of tissues
and cellular environments, composed of large numbers of
disparate yet interacting cell populations, makes this difficult.
RNA prepared from heterogeneous tissue samples might contain
only a fraction of the total cell subpopulation of interest [2].
Consequently, the expression signal of any gene detected directly
from a complex sample is a convolution of expressions of all
present cell types. Therefore, if tissues or cells are used without
consideration of such a mixing phenomenon, measurement of
differential gene expression will certainly be confounded by the
heterogeneous cell populations [3,4]. Similarily, heterogeneity of
cell populations across different samples could drown out the
variability resulting from other, perhaps more relevant differences
between samples [5].
There are several approaches used to identify changes in gene
expression that occur in different cellular compartments within
tissues or tumors comprised of multiple cell types. Microdissection
techniques that might allow a purer sampling of cells from fresh
tumor specimens is time-consuming and requires an amplification
of the sample that could distort transcriptional profiles [6]. Blood
cell-type subset composition can be measured by complete blood
counts (CBCs). CBCs typically offer a fixed, low resolution survey
of circulating cell populations. For example, a typical CBC will
provide one measurement that describes all circulating lympho-
cytes. Such data can not be used to tease apart contributions from
important cell populations including CD4+ and CD8+ T-cells, B-
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distinct lineage and carries out a different immunological purpose.
Nevertheless, it has been demonstrated that the incorporation of
CBC measurements helps ellucidate meaningful transcriptional
signals in blood [3].
The inversion of sample heterogeneity can be facilitated by
providing accurate estimates of the mixing percentages of different
cell types through computational deconvolution. Since computa-
tional dissection does not require microdissection of all samples or
change of routine biological protocols, several authors have tried to
answer whether it is possible to decompose the DNA microarray
datafroma cell populationto survey theproportions of differentcell
types, by treating specific transcriptional patterns in DNA
microarray data as cell-type-specific markers through computation-
al methods [3,5,7,8,9,10,11]. Lu et al. pioneered the application of a
simulated annealing-based algorithm to identify the proportions of
cells [11]. Abbas et al. [8] first applied microarray deconvolution for
measuring proportions of cell types in blood samples and employed
the results to study immune disease. Quon uses Latent Dirichlet
Allocation (LDA) to implement the deconvolution strategy in
conjunction with digital high-throughput sequencing data [9]. Very
recently, Shen-Orr et al. described cell-type-specific significance
analysis of microarrays (csSAM) for analyzing differential gene
expression for each cell type in a biological sample by incorporating
heterogeneity in gene expression [3]. Nevertheless, previously
developed approaches for tackling heterogeneity in transcriptional
profiling data from complex samples have several drawbacks which
we aim to address and alleviate in this study. Some methods can
only be applied to two-source systems; that is to say, complex
mixtures composed of only two tissue or cell types [7], which is not
practical for application to more complex samples. Other
approaches have been reported to deconvolute heterogeneous
expression profiles into their individual component profiles and
thereby infer the mixing proportions. However, these do not
guarantee a globally optimal solution, nor do they guarantee
physically meaningful solutions. These approaches use heuristic
methods that non-deterministically identify local optima [5,11], or
require ad hoc post-processing to eliminate non-physical results such
as negative mixing fractions [8].
What we sought to demonstrate here was an in silico approach to
deconvolute gene expression profiles obtained from heterogeneous
clnicial samples into cell-type-specific patterns when the mixing
matrix is unknown. We developed an approach built upon linear
latent variable models that efficiently identifies the globally optimal
solution in the least squares sense. Moreover, our approach
explicitly incorporated physical constraints, specifically the mixing
weights were required to be non-negative and sum to one, and
therefore generated results that can be directly interpreted as
mRNA mixing fractions. Technically, we employed a supervised
selection of cell-type-specific genes to provide a basis that
described the transcriptional state of ‘‘pure’’ cell populations.
These cell-type-specific transcripts were then used to deconvolute
the samples of interest using a quadratic programming technique
that was highly efficient, providing directly interpretable results
(i.e., the mixing fractions), and guaranteed to find the globally
optimal solution. The results demonstrated that our method was
able to accurately predict mixing fractions for more than ten
species of circulating cells, and was even able to provide accurate
estimates for relatively rare cell types.
Results
We implemented our procedure for estimating fractions of
different cell types in multiple gene expression data sets. First we
assessed the utility of our method by applying it to three well
controlled benchmark data sets with known mixing fractions.
Satisfied that our approach worked, we then applied it to more
challenging mRNA expression profiling data from human blood
samples collected as part of a clinical trial.
Proof of Concept: Deconvolution Accurately Predicts
Mixing Fractions
Datasets. We used three benchmark datasets as proof of
concept experiments. In the first experiment, tissues used for
microarray analyses included independent, triplicate pools of
blood and breast tissue samples from female adults. Double
standed cDNA synthesis and labeling was carried out with 5 mgo f
total RNA, each sample was hybridized to Human Genome 133
Plus 2.0 GeneChips as specified by the manufacturer and the
resulting CEL files were processed by Robust Multiarray Average
(RMA) normalization [12] and scaled to a 2% trimmed mean of
150. Six purified reference sample data files and nine other
mixtures included RNA from each of the two tissues at varying
proportions were summarized in Table 1. The array data can be
accessed via Gene Expression Omnibus (GEO), GSE 29832.
In the second experiment, we employed the MAQC Rat
Toxicogenomics Dataset [13] which includes RNA samples using
Rat Genome 230 2.0 GeneChips. The RNA derived from rat liver
and kidney bio-specimens from a single rat was mixed in four
different proportions, two of which were from each of the tissues in
isolate (100% liver and 100% kidney). The two other mixtures
included RNA from each of the two tissues are 75:25/25:75
respectively (Table S1). MIAME-compliant array data can be
accessed via Gene Expression Omnibus (GEO), GSE5350.
For the last benchmark dataset, we used rat liver and brain as
described in [3]. Each sample was hybridized to rat-specific
RAE230_2 whole-genome expression arrays (Affymetrix), and the
resulting CEL files were processed by RMA normalization for
deconvolution. Each of the samples was analyzed in triplicate. The
detailed mixture information is shown in Table S2. The
microarray data used in this study (series number GSE19830)
are available at NCBI-GEO [14].
Expression Signatures. Microarray expression data were
used to generate cell-type-specific gene lists through pairwise
comparisons of expression between all pure samples as described in
Materials and Methods. Statistical associations between GO annotation
and lists of differentially expressed genes were identified using
MetaCore
TM [15]. We applied the False Discovery Rate (FDR)
multiple testing correction [15] and applied a final cutoff of FDR
adjusted p,0.05 to identify statistically significant associations.
Inspection of annotation of identified gene list in blood vs. breast
cell line data confirmed this approach returned known cell specific
Table 1. Experimental design for blood vs. breast microarray
experiment.
T i s s u eT y p e %B l o o dm R N A %B r e a s tm R N A # Replicates
Pure 0% 100% 3
Mixed 33% 67% 6
Mixed 67% 33% 3
Pure 100% 0% 3
RNA derived from 15 female adults were homogenaized, extracted and mixed
in 4 different proportions, two of which are each of the tissues in isolate (100%
blood and 100% breast).
doi:10.1371/journal.pone.0027156.t001
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included genes whose expression is specific for blood specific genes
(BANK1, BCL11B), breast specific genes (ERBB3, CA12,
CCND1, ESR1) (Table S3). And all these genes are enriched in
cell cycle control, role APC in cell cycle regulation, the metaphase
checkpoint; human Cell-cycle/CDKN1A Mediated Pathway and
their enriched GO categories included mitosis (biological process),
M phase of mitotic cell cycle (biological process), M phase
(biological process), cytokinesis (biological process) and cell division
(biological process). These findings support the validity of this
approach to identify cell-type-specific genes. Detailed annotations
and Gene Ontology over-representation analyses are shown in
Table S3.
Expression Deconvolution on Cell Line Mixing
Experiments
First, we measured the accuracy of our method with three
benchmark experiments where known proportions of different
tissues or cells are mixed, assayed on expression microarrays, and
computationally separated.
In each case, we generated gene signatures by analyzing the
data from the ‘‘pure’’ samples (Training Data) and then applied
these signatures into our approach to estimate the mixing fractions
for the complex samples (Test Data). The results of the first
mixtures - blood vs. breast are as depicted to the Fig. 1(a). The
congruence between our predictions and the actual mixing
fractions suggests the validity of this deconvolution approach.
Secondly, we deconvoluted rat liver and kidney mixture dataset.
As expected, this algorithm also correctly estimated the compo-
sition of each of the 12 samples as consisting entirely of its
appropriate corresponding cell types (Fig. 1(b)). In the third
experiments, expression deconvolution was performed on data sets
of the mixture of rat liver and brain (Fig. 1(c)). These estimates
closely paralleled changes in component sizes that were observed
by known fractions, thereby confirming the validity of this
approach.
Deconvolution of Circulating Cells from Whole Blood
Samples
To test the utility of our algorithm to track clinically relevant
changes in blood populations, we applied our method to
expression profiling data generated for whole-blood samples
collected from Multiple Sclerosis patients (MS) treated with
Fingolimod (FTY720), a novel immunomodulator. Fingolomid is
a structural analog of sphingosine that, in its phosphorylated form
(FTY720-P), antagonizes S1P1 receptors expressed on the surface
of lymphocytes. This in turn prevents the egress of lymphocytes
from the lymph nodes, thereby impacting the trafficking of
lymphocytes in the circulation [16]. It was previously shown that
Fingolomid preferentially reduces the number of circulating CD4+
and CD8+ T-cells in human subjects [16].
Blood is a particularly complex tissue type, with over a dozen
distinct cell types that can vary in frequency up to 10,20-fold
between healthy individuals [3]. We applied our method to whole
blood samples, using previously published signatures [8] for 17
circulating cell types (Table S4). We aggregated our predictions
within three major cell types (lymphocytes, monocytes and
neutrophils) to facilitate direct comparison to the CBC results.
Agreement between our predictions and measured values was
excellent (Fig. 2), with Pearson correlation coefficients ranging
from 0.61 to 0.85. Agreement between predicted and measured
values was greatest for lymphocytes, which is notable due to the
complexity of sub-populations present in this fraction. In contrast,
previous attempts to deconvolute blood samples using the same
signatures have only achieved lower correlations against CBC data
(0.52 and below) [8]. As depicted in Fig. 2, agreement between
predicted and actual cell fractions shows good correlation, but
deviates from the diagonal. This can be attributed to intrinsic
differences in mRNA amounts per cell type and extrinsic
differences in mRNA yield. These deviations are linear in nature,
and therefore would not impact most downstream applications.
Inspection of the predicted mRNA fractions revealed that our
method was able to dissect the lymphocyte population and track
Figure 1. Statistical deconvolution of complex tissues yields accurate estimates of pure tissue fractions. Plotting of proportions of cell
lines determined from deconvolution (y axis) vs. proportions of the cell lines actually mixed (x axis) shows strong congruity. (a) Proportions of blood
cells determined by deconvolution are similar to proportions determined by actual blood fraction. Diagonal lines are y=x, shown for reference,
highlighting the agreement between the two methods. The training data in blue circles are from pure reference samples. The test data are from
mixed samples with various mixing proportions. (b) Proportions of liver fraction determined by deconvolution are similar to actual liver fraction. (c)
Proportions of liver cell lines determined from deconvolution vs. proportions of the cell lines actually mixed are shown a high consistency in rat liver
vs. brain dataset.
doi:10.1371/journal.pone.0027156.g001
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depicts a detailed breakdown of our predictions, stratified on
treatment group and time point. Our method correctly identified
reduction in circulating CD4+, CD8+, and B-cells following
Fingolomid treatment. Reductions relative to baseline were
significant for both treatment arms (p,0.01, Wilcoxon ranked
sum test). Several other populations had increases in their relative
predicted proportions in the treated subjects. Specifically, the
predicted relative abundance of monocytes, NK cells and dendritic
cells increased following Fingolomid treatment. These populations
are not sequestered in the lymph nodes following treatment by
Fingolomid, so their absolute numbers in circulation remain
unchanged. Because microarray data is inherently semi-quantita-
tive, we are only able to determine the relative abundance of each
cell type in a sample. Consequently, the relative abundance of the
cells appears to increase concomitant with the Fingolomid-induced
reduction in other lymphocytes. Notably, none of the populations
demonstrated changes in the placebo-treated subjects (p.0.4),
which suggested that our approach was capable of a high degree of
specificity even in complex, highly variable data sets.
Comparison to Other Methods
All surveyed microarray deconvolution methods make use of a
system similar to that described in equation (1), X=AS. They
differ substantially, however in how they dissect this system of
equations, their optimization methods, and other important
details. A summary of the methods surveyed here, and their main
characteristics can be found in Table 2.
These methods approach equation (1) in one of three ways: (A)
Given microarray data X and mixing fractions A, estimate the
basis matrix S. Shen-Orr et al. [3] used this approach to combine
cell count and microarray data as input for further analysis to
identify disease-associated transcriptional disregulation. (B) Given
microarray data X and basis matrix S, estimate the mixing
fractions A. Our approach falls into this category. (C) Given
microarray data X, simultaneously estimate the mixing fractions A
and basis matrix S. This approach is unsupervised. Consequently,
such methods require prior information to initialize the optimi-
zation [17], use non-deterministic optimizers that can become
trapped in local minima [18], must label the pure cell types in
post-processing steps [18], and vary in performance depending on
the amount of input data [18].
Immune cell-specific expression is a critical indication of a
gene’s role in the immune response [19]. Fortunately, a
compendium of microarray expression data for human genes
from key immune cell types has been compiled [19], making it
possible to supervise the decomposition with respect to these
known primary immune cell types and these subsets of genes. As a
demonstration, we applied our method, and two methods with
available source code [18] and [17] to two benchmark data sets.
These methods are designed to solve the more general and
challenging problem (category (C) above) of solving for cell
signatures and cell fractions simultaneously. Method [18] operates
in a completely unsupervised fashion, wheres method [17] requires
an initial estimate of the cell fractions. A direct comparison of the
performance of these methods is challenging, however we believe
it provides some insights into the relative strengths and weaknesses
of each, and helps to assess the importance of prior biological
knowledge when deconvoluting complex data. Our first bench-
marks were run on the blood/breast data set. The method of
Erkkila et al. [17] requires initial estimates of the mixing fractions.
To test this method, we provided it with initial estimates based on
the known fractions with Gaussian noise added at 20dB (i.e. 100:1
signal to noise ratio (SNR)). A second set of benchmarks were run
on the 24 whole-blood microarrays described in [3], and
compared to the published Complete Blood Counts (CBCs) to
assess accuracy. Again, we seeded method [17] with random
numbers, CBCs with 20dB Gaussian noise (100:1 SNR), and
CBCs with 10dB Gaussian noise (10:1 SNR) respectively. Results
are presented in Table 3. For the simple blood/breast system, all
methods performed well; performance for our method and
Repsilber et al. ’s [18] was similar (correlation .0.99) and slighlty
better than the performance of Erkkila et al. ’s approach [17]
(correlation .0.96). For the more complex blood sample, our
method and Repsilber et al. ’s performed similarly for neutrophils,
whereas ours performed substantially better for lymphocytes and
monocyte. Erkkila et al. ’s approach performed better than the
other methods when seeded with the actual CBC values with mild
Figure 2. Comparison of CBC data and statistical deconvolution in whole blood samples. Determination in whole blood samples of
relative abundance of total lymphocytes, neutrophils, or monocytes by CBC compared to determination of relative abundance by deconvolution.
Each green dot here corresponds to one sample in the dataset. Diagonal lines are y=x, shown for reference, highlighting the agreement between the
two methods.
doi:10.1371/journal.pone.0027156.g002
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tests with added noise. At 10 dB noise its performance drops but is
similar to the results of our method; in the absence of prior
information (i.e. seeded with random estimates) it could not find
any solutions. These benchmarks indicate that deconvolution
performance varies by the complexity of the experimental system,
and the availability of prior biological knowledge. Our method,
when fed with cell-type-specific transcriptional signatures, appears
to perform well across a number of different biological systems of
varying complexity. For the more general case in which both cell-
type-specific signatures and cell fractions are not known, the
performance of available methods varies substantially. For simple
systems with few cell types, all tested methods perform well. For
more complex systems, the use of accurate prior knowledge in the
form of signatures (our method) or accurate cell fraction estimates
(Erkkila et al. ’s method [17]) results in better performance. The
results from Repsilber el al. ’s method [18] indicates that
reasonable cell fraction estimates are still possible in the absence
of prior knowledge. Taken together, these results suggest that (1)
there is no one size fits all solution to this problem and (2) one
should take advantage of any available prior biological knowledge
when attempting to deconvolute transcriptional data.
Robustness of the Gene Signature Selection
The foundation for this approach is the identification of a set of
signatures that are generally representative of the cell types of
interest. Any errors or uncertainities introduced in the design of
this basis matrix could propogate through the analysis and impact
the final results. Our approach leverages the thousands of
expression level measurements made on each microarray to
Figure 3. Estimated fractions for several circulating cell populations. Strip charts display relating quality of CD4+ cells/CD8+/B cells/NK cells/
Monocytes/Dendritic cells. The data are stratified in three different subgroups: placebo (black), low dose: 1.25 mg/day (red) and high dose: 5 mg/day
(blue). Data points are from each donor. Y axis is the estimated mRNA fraction. P-values are calculated by Wilcoxon’s Signed Rank test.
doi:10.1371/journal.pone.0027156.g003
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can be optimally solved globally via quadratic programming.
Taken together, this strategy should be robust to small deviations
in the basis matrix; it uses many measurements of probes on the
chip (j.100) to estimate a small number of parameters in the
linear system (n,20), so errors in any one measurement should
have only a minimal effect on the final estimations. We performed
several simulations using the blood/breast data to verify the
robustness of our approach to fluctuations in the construction of
the basis matrix.
For the first simulation, we sought to address the impact of the
selection of differentially expressed genes inlcuded in the basis
matrix. There were 1320 differentially expressed probesets
identified in the blood/breast experiment. We randomly selected
either 100 or 200 probesets from these 1320 for inclusion in the
basis matrix and then estimated the mixing fractions using the new
basis matrices. This procedure was repeated 100 times. Results are
depicted in Fig. 4 panel (a). As expected, results were robust to the
precise selection of differentially expressed genes, with correlations
between estimated and actual fractions above 0.99 for almost all
simulated matrices.
We then examined the accuracy of our approach by increasing
the number of cell-type-specific gene probes stepwise from 40 to
1000. The correlation coefficients plot (Fig. 4(b)) shows that our
approach accurately estimated the mixing proportions as long as
the basis matrix includes at least 240 probesets. The estimation
could steadily achieve the correlation coefficient above 0.99.
Finally, the basis matrices might also be challenged through the
introduction of biological variability. Ideally, one would like to
construct basis matrices from training experiments that are as
similar as possible to the eventual test conditions. This however is
not always possible. Clinical samples are precious commodities,
cell-sorting techniques can be cumbersome or costly, and real-
world applications often involve systems perturbed by disease or
other interventions. We conducted several simulations to further
evaluate the generalizability of our approach when genes selected
for the basis matrix were differentially expressed in the test
systems. We randomly selected 5, 10, or 15 percent of the genes in
the basis matrix and altered their values by factors of +/22 fold
and +/25 fold. This process was repeated 100 times, and we
compared the estimates using the modulated basis matrices to the
actual fractions. The two-fold changes simulation results are
Table 2. Summary of current major deconvolution methods.
Decoupled/simultaneously
estimation
Deterministic/
probabilistic
Global/local
optimal solution
Non-negative
constraint
Related to
sample size
Source code
available
Our method Decoupled, estimate A deterministic global optimal solution by
quadratic programming
Yes No -
Abbas, plus ONE, 2009 Decoupled, estimate A deterministic Local No No No
Shen-Orr, Nature
Methods, 2010
Decoupled, estimate S deterministic Global No No Yes
Repsilber, BMC
bioinformatics, 2010
Simultaneously
estimate A and S
deterministic Local Yes No Yes
Erkkila, Bioinfoamtics,
2010
Simultaneously
estimate A and S
probabilistic Local Yes (implicitly) Yes Yes
Stuart, PNAS, 2004 Decoupled, estimate S deterministic Global No No No
Lu, PNAS, 2003 Decoupled, estimate A probabilistic,
simulated
annealing-based
algorithm
the probability that the
simulated annealing
algorithm terminates with
the global optimal solution
approaches 1 as the annealing
schedule is extended
Yes (implicitly) No The software
link no longer
works
doi:10.1371/journal.pone.0027156.t002
Table 3. The comparison of deconvolution methods on cell line data and Shen-Orr et al.’s 24 whole-blood microarray data.
Methods Breast/blood cell line data
Human whole-blood gene expression array data from kidney
transplant recipients
Neutrophils Lymphocytes Monocytes
Our method 0.9912 0.7198 0.6926 0.6492
Repsilber et al., BMC bioinformatics, 2010 0.9901 0.7092 0.4764 0.2783
Erkkila et al., Bioinformatics, 2010 - -0.1135
a 0.2926
a 0.1147
a
Erkkila et al., Bioinformatics, 2010 - 0.6324
b 0.7381
b 0.5359
b
Erkkila et al., Bioinformatics, 2010 0.9665
c 0.955
c 0.9094
c 0.8865
c
The numbers of the table showed the correlation coefficients between predicted and measured values for mixing proportions. For cell line data, we initialized the
mixing matrix for Erkkila et al.’s approach with measured CBC fractions added 20 dB noise
c. For Shen-Orr et al.’s data, we provided three different kinds of prior
knowledge for the initialization of mixing matrix for Erkkila et al.’s approach: random numbers from normal (or Gaussian) distribution as the mixing fraction
a, measured
fractions with 10 dB noise
b and measured fractions with 20 dB noise
c. We aggregated our predictions within three major cell types (neutrophils, lymphocytes and
monocytes) to direct compare to the CBC results.
doi:10.1371/journal.pone.0027156.t003
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are presented in Fig. S4. Fig. 5(a) illustrates that our algorithm still
achieves very significant accuracy with the correlation coefficients
between the estimated and measured proportions above 0.99. This
is true even in the extreme case where 15% of the genes in the
basis matrix are changed.
These three sets of simulations demonstrate that our approach –
an overdetermined system of equations coupled to efficient global
optimization – is robust against the kind of biological and technical
noise we expect to see in real world applicaitons.
Discussion
We have developed a novel computational approach for
deconvoluting mRNA expression profiling data from complex
samples into contributions from an aribirtrary number of cell types
for which prior biological knowledge is available. We built upon
the well accepted practice of describing such data as a system of
linear equations through the introduction of a least squares
solution with equalities and inequalities that can be optimally
solved via quadratic programming. The use of quadratic
programming has several advantages over methods previously
used to address this problem. Specifically, this approach allows for
the explicit modeling of physical constraints in both the description
of the problem as well as its solution. Application of equalities and
inequalities in turn enables direct interpreation of the results as
mRNA proportions. In addition, the introduction of quadratic
programming as an optimizer provides a computationally efficient
algorithm that gurantees the identification of a globally optimal
solution to the system of equations. The introduction of quadratic
Figure 4. Robustness of the signature matrix. (a) Boxplot displaying robustness of chosen signature matrix to gene content. The correlation
coefficient distribution (Y axis) is depicted for signatures composed of 100 or 200 randomly selected differentially expressed probesets. (b)
Deconvolution performance across a range of signature sizes. The experiment is conducted by increasing the number of cell-type-specific gene
probes step-wisely from 40 to 1000.
doi:10.1371/journal.pone.0027156.g004
Figure 5. Stability of the signature matrix. (a) Boxplot displaying the stability of chosen signature matrix. The chosen signatures are distorted by
randomly selecting 5, 10, or 15 percent of its genes and randomly modulating their values with 2 fold changes. The distribution of correlations
between actual mixing fractions and fractions estimated using these signatures is depicted. (b) Condition number of the basis matrix with respect to
the percentage of simulated differentially expressed genes in the basis matrix.
doi:10.1371/journal.pone.0027156.g005
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namely how best to solve the system of equations used to represent
complex microarray data. Going forward, we believe there is still
substantial room to improve other aspects of this framework. As
examples, the generation of cell-specific signatures is still a largely
heuristic endeavor, and the lower limits of detection of rare cell
types remains largely uncharacterized.
Our approach yielded predictions with excellent agreement to
measured values across a number of simple controlled mixing
experiments. Through the use of accurate transcriptional signatures
for various circulating cell types, we have demonstrated that our
method is capable of generating accurate predictions of even rare
cell types in complex blood samples. Moreoever, this approach has
clearlydemonstratedanabilitytotrackclinicallyrelevantchangesin
blood populations that would be missed in standard CBCs.
Thiswork provides a critical step toward the improved analysis of
transcriptional data derived from complex clinical samples. In the
case decribed here, our method was able to accurately predict drug-
induced changes in lymphocyte trafficking based solely on mRNA
expression profiling data. These and other changes in cicrulating
cell populations in clinical settings are of sufficient magnitude to
dominate the signals measured via transcriptional profiling, and
would color any analysis that does not account for them. Previous
work has suggested that it is possible to dissect cell-specific
transctiptional changes in silico [3] using CBC data as a guide post.
Our methodology and results allow for a much finer grained view of
cell heterogeneity that should enable moreprecise in silico dissection.
Looking forward, we see several natural extensions of our
method. The rapid adoption of Next Generation Sequencing
platforms (NGS) promises the delivery of increasingly higher
resolution views of the transcriptome. Data from such RNA-Seq
experiments is already providing more exquisite views of low-
abundance transcripts and alternative splicing [20]. Identification
of new transcriptional species is likely to make deconvolution more
sensitive and accurate. The ability to detect low-abundance
transcripts should allow us to detect rarer cell populations, while
the broader sampling of the transcriptome should aid in the
idenfitication of cell-type-specific isoforms that will more precisiely
delineate closely related cell populations. This is likely to be of
great importance in the application to blood samples, where
increased resolution and sensitivity would allow us to differentiate
between clinically relevant subpopulations (e.g. Th1, Th2, and
Th17 CD4+ T-cells). Another natural example would be
application to metagenomics experiments to explicitly estimate
the relative abundance of various microorganisms based on the
abundance of their DNA in a sample.
In general, the application of highly sensitive, high throughput
experimental technologies to complex biological samples will
require increasing sophistication in the way that we think about
and analyze our data. In some cases, this complexity has the
potential to obfuscate relevant phenomenon if not addressed. In
others, accurately estimating the complexity itself can be a useful
endpoint. The approach we introduced here represents one
specific application of a general framework for explicitly handling
such complexities. The mathematical underpinnings and optimi-
zation algorithm are agnostic to the details of the biological system,
and are generalizable to other data types that can be described via
a system of overdetermined linear equations.
Materials and Methods
Patients and Whole Blood Smaples
Whole blood transcriptional analysis was performed as part of a
clinical trial [21] (CFTY720D2201, a double-blind, randomized,
placebo-controlled, parallel-group, multicenter study evaluating
the safety, tolerability and effect on MRI lesion parameters of
Fingolomid vs. placebo in patients with relapsing multiple sclerosis)
(ClinicalTrials.gov identifier NCT00333138). Patients meeting
pre-defined disease criteria were treated with Fingolomid at one of
two doses (5 mg/day, 1.25 mg/day) or with placebo [16]. The
study adhered to the International Conference on Harmonization
Guidelines for Good Clinical Practice and was conducted in
accordance with the Declaration of Helsinki [22,23]. All patients
gave written informed consent. Characteristics of patients are
given in [16]. Whole blood samples were collected in PAXGene
tubes for cDNA microarray analysis at baseline (pre-treatment)
and at six months after treatment commenced. Samples were then
analyzed as described above. The data were also pre-processed
using RMA [12] and scaled to a 2% trimmed mean of 150.
Latent Variable Model
Estimating the proportions of different cell types is based upon a
latent variable model framework [24,25]:
X~AS, ð1Þ
where X is the microarray data from complex biological samples,
A is the set of unknown proportions of the cellular constituents of
X, and S is the known matrix of expression levels of the genes in all
the cellular constituents of X.
Based on this model, we will first describe how we modeled the
total expression signal of each microarray probe as the sum of the
expression signals of its constituent parts in each mixture sample
and solve it in constrained linear least-squares problems. We will
then describe the identification of expression signatures using
Limma (Linear Models for Microarray Data) [26] for differential
expression analysis and how to estimate the number of expression
signatures through condition number of the signature matrix.
Computational Deconvolution by Linear Least-square
Problems
Expression deconvolution, which takes advantage of the linear
latent model to represent the original expression signals as a
mixture of each compartment signal, was performed on linear,
untransformed data as follows. Starting from Eq. (1), the
expression level xjk of gene j in a sample k is the average of cell
type expectations, sij, weighted by cell type fractions aki:
xjk~
X
i
akisij: ð2Þ
For one probeset, we had many more unknown fractions of
mRNA (aki) in the sample than known expression level measured
on the chip (xjk), so the system was underdetermined.
For multiple probesets, we could extend this to a system of
linear equations:
x1k~ak1s11zak2s21z   zaknsn1
x2k~ak1s12zak2s22z   zaknsn2
. .
.
xjk~ak1s1jzak2s2jz   zaknsnj:
ð3Þ
When j.n (more probesets than cell types), this system of
equations is over determined. Physical constraints could be
explicitly added to this system. Microarray data sets are inherently
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tions of mRNA present from each cell type, and these proportions
must sum to one:
P
i
aki~1. In addition, to insure a physical
solution, we required that all mRNA fractions must be non-
negative: aki§0,Vi.
Ideally, we would like to find mRNA fractions (aki) that satisfy:
As{x~0. We were unlikely to find such solutions in noisy
biological systems. We could, however, find an optimal (aki) that
minimizes the residuals for As{x~0 in the least squares sense:
min As{x kk
2
  
, s:t:
P
i
aki~1
aki§0,Vi
(
ð4Þ
where the coefficient aki is a scalar parameter between 0 and 1 to
represent the fraction of cell subtype. When linear non-negative
inequalities and equalities were given, Eq. (4) could be solved with
quadratic programming [27]. We solved this series of equations
using the lsqlin function in MATLAB.
It should be noted that this approach has been previously used
for deconvoluting populations in complex biological samples,
albeit in a completely different setting. Specifically, Mackey et al.
introduced this approach to successfully estimate the contributions
of different phytoplankton classes in oceanic samples based on
HPLC measurements of various pigment concentrations [28].
This method is very general and could easily be applied to other
data types as well (see Discussion). It also has several clear
advantages over approaches reported elsewhere. Explicit incorpo-
ration of the non-negativity constraint allows clear physical
meanings for the solution, which can be directly interpreted as
mRNA fractions. Therefore, we do not need to remove the lowest
negative coefficient from the equation as in [8], or apply an
iterative approach of the solution until all coefficients were
nonnegative [5,11]. Moreover, this system satisfies the criteria
necessary to be solvable by quadratic programming, which
therefore guarantees a globally optimal solution. Finally, quadratic
programming routines are readily available and highly optimized.
Solutions even for experiments with hundreds or thousands of
samples can be rapidly and efficiently identified on a standard
computer workstation.
Expression signature identification
Expression signatures of homogeneous samples of cells are
critical to model the cellular composition of complex tissues. Such
signatures provide prior biological knowledge about the ‘‘baseline’’
physiological condition of each cell type. On balance, it is assumed
that the baseline condition is represented in complex environ-
ments. Generally, many genes remain unchanged across different
phenotypes or phenotypic changes [29,30]; only a subset of the
entire gene set potentially discriminates between cell types and
may be used to estimate the mixing parameters and represent the
pure signals. Hence, only those genes that are able to differentiate
cell types of interest are useful as a basis set for microarray
deconvolution.
We further reasoned that the expression profiles for high and
low abundance genes could fall outside of the linear range of the
microarrays, especially in artificial cell line experiments. We
observed that there are huge fold changes between different
tissues, and therefore only included the genes with the expression
value within the range of 0.1,5000.
The probesets comprising the basis for deconvolution were
determined as follows. First, the differential expression of each
gene for different tissues or phenotypes was assessed by linear
modeling and empirical Bayes methods using Limma (version
3.2.3, [26]) from the Bioconductor project [29]. Genes with an
adjusted p-value (FDR),1e-5 were retained for further evaluation.
In the next step, we wanted to adjust the number of genes included
in the signature to derive a high performance basis matrix that
would be attributable to the estimated proportions. Following [8],
probesets were ranked by their degree of differential expression
according to the absolute t-statistic, and a complete set of matrices
comprised of different quantities of the most differentially-
expressed probesets was tested by comparing the results of each
matrix to the known mixture fractions. A matrix’s condition
number estimates the sensitivity of a system of linear equations to
errors in the data. Consistent with [8], we also observed that the
condition number tracked with the accuracy of predictions in a
largely continuous fashion (Fig. S1(a)). Additional plots of
condition number as a function of matrix size for the liver/kidney
and liver/brain experiments are provided in Figs S2 and S3 and
their detailed gene lists are in Table S3. These systems had optimal
matrices with 210 and 160 probesets, respectively. To test the
feasibility of using the condition number as an appropriate
selection marker to generate baseline transcriptomes representing
genome-wide profiles for different tissues, we did the following
experiments.
We validated the ‘optimal’ number of expression signatures in
terms of condition number [8] by testing the relationship between
the goodness of fitting and different quantities of the most
differentially-expressed probesets. Overall, experimentally mea-
sured root mean square deviation (RMSD) between the estimated
fractions and the actual fractions correlated very closely with how
well conditioned (i.e., condition number) each matrix (Fig. S1 (b),
Fig. S2 (b) and Fig. S3 (b)). And the RMSD of the fitting residual
also had high correlation with the condition number (Fig. S1 (c),
Fig. S2 (c) and Fig. S3 (c)). When we selected the ‘optimal’ number
of expression signature, the slope of the RMSD of the fitting
residual began to gently ease off. All these results supported us to
select condition number as a high-fidelity marker for the ability of
a basis matrix to accurately deconvolute the mixtures.
In this manner, we obtained optimized size of expression
signatures for cell-type-specific genes from each purified reference
sample and averaged across samples obtained from the same cell
or tissue type. These signatures were taken as estimates of basal
expression for computationally deconvolution of mixed samples.
Supporting Information
Figure S1 Condition number of signature basis matrix
varies with number of probesets included. (a) Function of
the condition number vs. the number of probesets from the gene
signature was characterized in blood and breast mixture cell lines.
The local minima of condition number is shown in green line and
the corresponding number of genes was selected as the ‘optimal’
number of expression signature; (b) Root mean square deviation
(RMSD) between the estimated fractions and the actual fractions
showed clear patterns to support the ‘optimal’ number of
expression signature selected in (a). To the right of the green line,
the RMSD almost formed a horizontal line with minor
oscillations, suggesting that increasing the number of genes would
not increase the accuracy of the deconvolution estimates. (c) The
RMSD of the fitting residual also had high correlation with the
condition number. This correlation is weaker when selecting more
than the ‘optimal’ number of genes (shown in green line here).
(TIF)
Figure S2 Condition number varies with the number of
probesets included in liver/kidney signatures. (a) Func-
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gene signature was characterized in rat liver and kidney mixture
cell lines. The local minima of condition number is shown in green
line and the corresponding number of genes was selected as the
‘optimal’ number of expression signature; (b) shows the relation-
ship between the RMSD of the estimated fractions and the
number of genes in basis matrix; (c) is the plot of the RMSD of the
fitting residual vs. the number of genes in basis matrix.
(TIF)
Figure S3 Condition number varies with the number of
probesets included in liver/brain signatures. (a) Function
of the condition number vs. the number of probesets from the gene
signature was characterized in rat liver and brain mixture cell
lines. The local minima of condition number is shown in green line
and the corresponding number of genes was selected as the
‘optimal’ number of expression signature; (b) shows the relation-
ship between the RMSD of the estimated fractions and the
number of genes in basis matrix; (c) is the plot of the RMSD of the
fitting residual vs. the number of genes in basis matrix.
(TIF)
Figure S4 Stability of chosen signature matrix. (a)
Boxplot displaying the stability of chosen signature matrix. The
chosen signatures are distorted by randomly selecting 5, 10, or 15
percent of its genes and randomly modulating their values with 5
fold changes. The distribution of correlations between actual
mixing fractions and fractions estimated using these signatures is
depicted. (b) Condition number of the basis matrix with respect to
the percentage of simulated differentially expressed genes in the
basis matrix.
(TIF)
Table S1 Experimental design for rat liver vs. kidney
microarray experiment.
(DOC)
Table S2 Experimental design for rat brain vs. liver
microarray experiment.
(DOC)
Table S3 Gene Annotation for blood vs. breast, liver vs.
kidney and liver vs. brain experiments.
(XLS)
Table S4 Leukocyte types used as the basis for whole
blood deconvolution.
(DOC)
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